Asterias maintains an extensive global intellectual property portfolio including broad issued claims to fundamental platform technologies including, but not limited to, scalable growth of pluripotent stem cells,
methods of production and compositions of matter for
several hESC - derived
therapeutic cell types, and cellular immunotherapy using the telomerase antigen.